Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.

Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ.

Nature. 2008 Jun 26;453(7199):1258-61. doi: 10.1038/nature06956. Epub 2008 May 14.

PMID:
18480754
2.

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

McKimm-Breschkin JL.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:25-36. doi: 10.1111/irv.12047. Review.

3.

Recent advances in neuraminidase inhibitor development as anti-influenza drugs.

Feng E, Ye D, Li J, Zhang D, Wang J, Zhao F, Hilgenfeld R, Zheng M, Jiang H, Liu H.

ChemMedChem. 2012 Sep;7(9):1527-36. doi: 10.1002/cmdc.201200155. Epub 2012 Jul 16. Review.

PMID:
22807317
4.

Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.

Ikematsu H, Kawai N.

Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Review.

PMID:
21973296
5.

Systematic review of influenza resistance to the neuraminidase inhibitors.

Thorlund K, Awad T, Boivin G, Thabane L.

BMC Infect Dis. 2011 May 19;11:134. doi: 10.1186/1471-2334-11-134. Review.

6.

Neuraminidase inhibitor resistance in influenza viruses.

Reece PA.

J Med Virol. 2007 Oct;79(10):1577-86. Review.

PMID:
17705169
7.

Rational development of neuraminidase inhibitor as novel anti-flu drug.

Chintakrindi A, D'souza C, Kanyalkar M.

Mini Rev Med Chem. 2012 Oct;12(12):1273-81. Review.

PMID:
22512586
8.

Influenza viruses resistant to neuraminidase inhibitors.

Nitsch-Osuch A, Brydak LB.

Acta Biochim Pol. 2014;61(3):505-8. Epub 2014 Sep 8. Review.

9.

Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.

Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R.

Infect Disord Drug Targets. 2013 Feb;13(1):34-45. Review.

PMID:
23675925
10.

Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses.

Govorkova EA.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:50-7. doi: 10.1111/irv.12044. Review.

11.

Influenza virus resistance to neuraminidase inhibitors.

Samson M, Pizzorno A, Abed Y, Boivin G.

Antiviral Res. 2013 May;98(2):174-85. doi: 10.1016/j.antiviral.2013.03.014. Epub 2013 Mar 22. Review.

PMID:
23523943
12.

Influenza virus susceptibility and resistance to oseltamivir.

Aoki FY, Boivin G, Roberts N.

Antivir Ther. 2007;12(4 Pt B):603-16. Review.

PMID:
17944268
13.

[Drug-resistant influenza viruses: an overview].

Hatakeyama S.

Nihon Rinsho. 2010 Sep;68(9):1671-8. Review. Japanese.

PMID:
20845746
14.

[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].

Ferraris O, Escuret V, Bouscambert-Duchamp M, Lina B, Morfin F.

Pathol Biol (Paris). 2010 Apr;58(2):e69-78. doi: 10.1016/j.patbio.2010.01.011. Epub 2010 Mar 19. Review. French.

PMID:
20303677
15.

[Neuraminidase inhibitors and risk of H5N1 influenza].

Gras-Masse H, Willand N.

Ann Pharm Fr. 2007 Jan;65(1):50-7. Review. French.

PMID:
17299351
16.

The potential impact of neuraminidase inhibitor resistant influenza.

Lackenby A, Thompson CI, Democratis J.

Curr Opin Infect Dis. 2008 Dec;21(6):626-38. doi: 10.1097/QCO.0b013e3283199797. Review.

PMID:
18978531
17.

Treatment options for H5N1: lessons learned from the H1N1 pandemic.

Reece PA.

Postgrad Med. 2010 Sep;122(5):134-41. doi: 10.3810/pgm.2010.09.2210. Review.

PMID:
20861597
18.

Issues in pharmacotherapy of 2009 H1N1 influenza infection.

Gupta YK, Padhy BM.

J Postgrad Med. 2010 Oct-Dec;56(4):321-7. doi: 10.4103/0022-3859.70945. Review.

19.

Oseltamivir.

Tullu MS.

J Postgrad Med. 2009 Jul-Sep;55(3):225-30. doi: 10.4103/0022-3859.57411. Review.

20.

Inhibitors targeting the influenza virus hemagglutinin.

Li F, Ma C, Wang J.

Curr Med Chem. 2015;22(11):1361-82. Review.

PMID:
25723505
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk